Providing researchers with the right information at the right time is a way pharmaceutical companies focused on new therapeutic solutions can advance product development. But when copyright compliance for a global workforce is factored in, accessing, and collaborating on that scientific information can become tricky.

BIAL faced four key challenges when it came to managing information across the enterprise: speed, accuracy, coverage, and availability.

To combat these challenges, BIAL secured a Multinational Copyright License, so employees could collaborate with team members, store articles for later use, provide required information to regulatory officials, and make it easy for employees to remain compliant.

Alongside internal research, BIAL also wanted to have the legal ability to collaborate with external teammates when doing a joint project. That’s why, in addition to the Multinational License, BIAL utilizes the Collaboration Amendment, a complimentary add-on that allows collaboration under the terms and conditions of the license among those team members of two licensed organizations who are working together on a joint project.

[Implementing a knowledge sharing culture] is not just talking about information management. It’s something that needs to be breathing and part of BIAL’s DNA...In our society people often think that content is for free or there is the common misperception that content can freely be re-used. That’s obviously not the case. We have to respect that a piece of content is someone else’s intellectual property.

Teresa Silveira Global Scientific Information Manager at BIAL

About BIAL

BIAL is an innovative pharmaceutical company. Founded in 1924, BIAL's mission is to discover, develop and provide new therapeutic solutions. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company headquarters are located in Portugal. BIAL has also facilities in the main European markets - Spain, Germany, United Kingdom, Italy, Switzerland -, Mozambique, Angola, Panama and Ivory Coast. In the US, BIAL has established BIAL Biotech Investments Inc. a research center focused on genetically-defined Parkinson’s disease.